At-Home Fertility Hormone Test Panels Market Global Report 2026

The at-home fertility hormone test panels market size has grown rapidly in recent years. It will grow from $4.96 billion in 2025 to $5.55 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to increasing infertility prevalence, growing awareness of reproductive health, rising demand for home-based diagnostics, expanding access to fertility testing services, and increasing trends toward delayed parenthood.

The at-home fertility hormone test panels market size is expected to see rapid growth in the next few years. It will grow to $8.64 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to rising demand for personalized fertility monitoring, increasing adoption of preventive reproductive healthcare, growing acceptance of self-testing solutions, expanding availability of digital diagnostic services, and increasing focus on family planning. Major trends in the forecast period include increasing adoption of at-home fertility testing, growing demand for early fertility assessment, rising preference for non-invasive hormone testing, expanding direct-to-consumer diagnostic services, and growing consumer awareness of reproductive health.

The rising infertility rates globally are expected to drive the growth of the at-home fertility hormone test panels market in the coming years. Infertility refers to the inability to achieve pregnancy after a prolonged period of regular unprotected intercourse, typically due to reproductive health issues affecting either partner. Infertility rates are increasing due to delayed parenthood, as advancing age can reduce reproductive potential and fertility outcomes, contributing to a higher prevalence of infertility. At-home fertility hormone test panels support individuals affected by infertility by providing accessible, private, and convenient fertility assessment tools that help monitor reproductive hormone levels and identify potential fertility concerns at an early stage. For instance, in October 2024, according to the Office for National Statistics (ONS), a UK-based government department, the total fertility rate (TFR) in England and Wales declined to a record low of 1.44 children per woman in 2023, compared with 1.49 in 2022. Therefore, the rising infertility rates globally are driving the growth of the at-home fertility hormone test panels market.

Major companies operating in the at-home fertility hormone test panels market are focusing on developing advanced connected testing devices, such as app-integrated hormone monitors, to provide couples with shared, real-time visibility into fertility hormone patterns rather than isolated individual results. A connected hormone testing device refers to an at-home diagnostic tool that measures fertility-related hormone biomarkers and synchronizes the results directly with a companion mobile application, allowing users to track cycle, ovulation, and hormone data alongside a partner. For instance, in June 2026, Vespexx Inc., a South Korea-based femtech company, officially launched Soonr Health in the US to enhance women’s health management through AI-powered cycle tracking, personalized reproductive health insights, symptom monitoring, and predictive wellness recommendations. Soonr Health combines cycle and ovulation tracking, habit and symptom logging, partner-aware sharing, and integrated at-home hormone testing, with both partners using the application on their own phones.

In July 2023, Quest Diagnostics Incorporated, a US-based healthcare company, partnered with Proov to commercialize fertility testing. Through this partnership, Quest Diagnostics aimed to expand its women’s health and fertility testing portfolio by offering Proov’s at-home fertility hormone testing solutions through its direct-to-consumer platform, improving access to fertility assessment and reproductive health insights. Proov is a US-based women’s health diagnostics company that develops at-home fertility and hormone testing products.

Major companies operating in the at-home fertility hormone test panels market are Abbott Laboratories, Church & Dwight Co. Inc., Swiss Precision Diagnostics GmbH, Everly Health Inc., Ro Health Inc., LetsGetChecked Inc., Easy Healthcare Corporation, Mira Fertility Inc., Inito Inc., Sugentech Inc., Fairhaven Health LLC, Fertility Focus Limited, GiveLegacy Inc., MFB Fertility Inc., Ava AG, Hertility Health Ltd., Oova Inc., ExSeed Health, Fellow Health Inc., Inne Bioscience GmbH, Arva Health.

North America was the dominant region in the at-home fertility hormone test panels market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the at-home fertility hormone test panels market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the at-home fertility hormone test panels market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.